SCHEMBL4356918

SCHEMBL4356918

O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 9/20 0.56
JAK2 O60674 11/20 0.44
JAK1 P23458 11/20 0.44
JAK3 P52333 11/20 0.44
STK4 Q13043 1/20 0.44
STK3 Q13188 1/20 0.44
STK26 Q9P289 1/20 0.44
STK24 Q9Y6E0 1/20 0.44
TYK2 P29597 10/20 0.44
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4364616 0.99 ALK (0.55) ALKJAK2JAK1JAK3STK4
SCHEMBL4366625 0.94 ALK (0.58) ALKJAK2JAK1JAK3STK4
SCHEMBL4366199 0.93 ALK (0.57) ALKJAK2JAK1JAK3STK4
Hydrochloric Acid SCHEMBL4353873 0.92 ALK (0.56) ALKJAK2JAK1JAK3STK4
SCHEMBL4361723 0.91 ALK (0.54) ALKJAK2JAK1JAK3STK4
SCHEMBL4360741 0.91 ALK (0.56) ALKJAK2JAK1JAK3STK4
SCHEMBL1073663 0.90 ALK (0.56) ALKJAK2JAK1JAK3STK4
SCHEMBL4361863 0.90 ALK (0.53) ALKJAK2JAK1JAK3STK4
SCHEMBL4353494 0.90 ALK (0.54) ALKJAK2JAK1JAK3STK4
SCHEMBL1076247 0.90 ALK (0.56) ALKJAK2JAK1JAK3STK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US claimed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US claimed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALK 3/4885JAK2 1/4885JAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.